Cybin Inc. Common Shares CYBN 深 滬
等待開盤 12-06 09:30:00 美东时间
5.99
+0.040
+0.67%
華盛通- 最 高6.20
- 今 開6.00
- 成交量 41.29万股
- 最 低 5.97
- 昨 收 5.95
- 總市值 1.51亿
- 52周最高 10.73
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 4.81
- 委 比 0.00%
- 總股本 2518.82万
- 歷史最高 122.36
- 量 比 0.62
- 振 幅 3.87%
- 歷史最低 4.81
- 每 手 1
- 風險率 1.35%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 美鹰服饰、CrowdStrike、迈威尔科技获多家机构上调目标价；ACHC、GitLab、Okta遭多家机构下调目标价
今日重点评级关注：Guggenheim：维持Cybin Inc. Common Shares"买入"评级，目标价从39美元升至48美元；HC Wainwright & Co.：维持Capricor Therapeutics"买入"评级，目标价从24美元升至60美元
12-04 09:38
Guggenheim Maintains Buy on Cybin, Raises Price Target to $48
Guggenheim analyst Eddie Hickman maintains Cybin (AMEX:CYBN) with a Buy and raises the price target from $39 to $48.
12-04 00:05
美股大行评级 | 最高352美元！14家机构连夜上调英伟达目标价；劳氏、塔吉特、Wix.com等遭多家机构下调目标价
今日重点评级关注：Ascendiant Capital：维持Aclarion"买入"评级，目标价从22美元升至23美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从24美元升至26美元
11-21 15:50
Canaccord Genuity Maintains Buy on Cybin, Lowers Price Target to $45
Canaccord Genuity analyst Sumant Kulkarni maintains Cybin (AMEX:CYBN) with a Buy and lowers the price target from $70 to $45.
11-21 00:02
Cybin Q2 EPS $(1.39) Misses $(1.09) Estimate
Cybin (AMEX:CYBN) reported quarterly losses of $(1.39) per share which missed the analyst consensus estimate of $(1.09) by 27.52 percent. This is a 33.81 percent increase over losses of $(2.10) per share from the same
11-13 20:27
Earnings Scheduled For November 13, 2025
Companies Reporting Before The Bell • Edgewell Personal Care (NYSE:EPC) is proj...
11-13 19:11
Cybin announces $175 million registered direct offering
Cybin (NYSE:CYBN) on Tuesday announced a registered direct offering of 22.2M common shares in the capital of the company and, in lieu of common shares to certain investors, pre-funded common share pur...
10-28 20:24
'Psychedelics Show Promise As An 'Entirely New Type Of Anti-Inflammatory Treatment,' Research Suggests' - Marijuana Moment
https://www.marijuanamoment.net/psychedelics-show-promise-as-an-entirely-new-type-of-anti-inflammatory-treatment-research-suggests/
10-14 01:28
'New York Lawmakers Hold Hearing Psilocybin's Medical Benefits Amid Broader Debate Over Psychedelics Reform' - Marijuana Moment
https://www.marijuanamoment.net/new-york-lawmakers-hold-hearing-psilocybins-medical-benefits-amid-broader-debate-over-psychedelics-reform/
10-02 23:03
Cybin Advances Clinical Programs in Psychedelic Therapeutics
An update from Cybin ( ($TSE:CYBN) ) is now available. Cybin has announced sign...
09-24 05:47
